Today: 15 May 2026
P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit
24 April 2026
2 mins read

P&G Beats Wall Street, Then Warns of a $150 Million Cost Hit

April 24, 2026, Cincinnati—08:11 EDT.

Procter & Gamble topped Wall Street’s profit and sales forecasts Friday, lifted by stronger demand for its beauty and hair-care lines. Still, the company behind Tide and Olay flagged rising commodity costs, linked to the Middle East conflict, as a drag on earnings for the remainder of its fiscal year.

This update lands at a tricky moment for the consumer goods group, with volume growth finally returning just as oil, packaging, and freight expenses start to bite. P&G is now guiding fiscal 2026 earnings toward the low end of its stated range, though it hasn’t changed the range itself.

P&G posted net sales of $21.2 billion for its fiscal third quarter, a 7% increase from last year. Core earnings per share came in at $1.59, up 3%, edging past the $1.56 consensus from Reuters. Revenue cleared analysts’ expectations too, beating the $20.50 billion figure from the LSEG survey.

Organic sales climbed 3%, leaving out the effects of currency swings, deals, or asset sales. That number outpaced every analyst forecast tracked by Bloomberg, notching P&G’s biggest organic gain in over a year.

It wasn’t only about price this quarter. P&G reported a 2% bump in organic volume, with beauty leading—volumes there climbed 5%. Beauty organic sales moved up 7%, thanks to hair care, personal care, and skin care. As for grooming and health-care, volumes slipped.

Chief Executive Shailesh Jejurikar described the results as a “solid acceleration” in top-line growth, adding that P&G plans to boost investment even as it navigates a “challenging geopolitical and economic environment.” Every one of the company’s 10 product categories posted organic sales growth for the quarter, according to Procter & Gamble. Procter Gamble

The cost side is proving tough. P&G projects an after-tax hit of around $150 million from commodities in fiscal 2026, with tariff expenses expected to tack on another $400 million. Offsetting some of that: a $200 million lift from foreign exchange. All in, management figures these factors will shave 25 cents off per-share earnings.

Procter & Gamble CFO Andre Schulten told CNBC that $100 per barrel oil would hit the company with an estimated $1 billion after-tax cost for the year, Reuters reported in a MarketScreener news flash.

Margins took a hit. P&G’s reported gross margin dropped 1.5 percentage points year over year, and core gross margin slipped by 1 point—pressured by mix, reinvestment, tariffs, and higher commodity costs. Productivity gains and price hikes cushioned some of the blow, the company noted.

P&G shares ticked up ahead of the bell after the report landed. Reuters reported a roughly 2% gain in premarket action, suggesting investors were shrugging off the cost warning—at least for now—thanks to sales and volume figures that cleared a low bar.

Peers aren’t seeing the same trends. According to Reuters, Nestle flagged higher costs tied to the Strait of Hormuz blockade. Over at L’Oreal, sales of premium hair care and fragrances stayed solid in North America and Europe. And Beiersdorf, for its part, hasn’t ruled out price hikes if commodity costs push higher.

The downside risk isn’t minor. A P&G spokesperson told Reuters that if the conflict continues, cost pressures could ramp up as early as the first quarter of fiscal 2027. The company, notably, hasn’t provided any guidance for fiscal 2027. When it comes to tariff refunds, the timeline is still unclear.

P&G left its fiscal 2026 sales growth projection unchanged at 1% to 5% and stuck to the same core EPS range, $6.83 to $7.09. The company is also holding steady on plans for about $10 billion in dividends and around $5 billion in buybacks this fiscal year.

Stock Market Today

  • BofA Strategist Hartnett Signals June Stock Market Profit-Taking Opportunity
    May 15, 2026, 6:37 AM EDT. Bank of America strategist Michael Hartnett warns the stock market is primed for profit-taking in early June. He points to investors' heavy equity positions and escalating inflation risks as key drivers. Hartnett's view signals traders may start selling shares to lock in gains amid economic uncertainties, impacting market momentum.

Latest articles

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead

15 May 2026
Murano Global Investments shares surged 67% to $0.49 in U.S. premarket trading Friday on heavy volume, after weeks under pressure from debt issues and a Nasdaq listing warning. The stock closed at $0.29 Thursday and faces an Oct. 5 deadline to regain compliance with Nasdaq’s $1 minimum bid rule. Murano is late filing its annual report and has warned of “substantial doubt” about its ability to continue as a going concern.
Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

15 May 2026
Mobix Labs shares jumped 78.74% to $3.11 Thursday after it signed a non-binding letter of intent to acquire Special Project Delivery, a U.S. critical-minerals and energy-storage platform. The company also amended a convertible note with Leviston Resources, raising principal to $4 million for $833,000 in new cash. SPD was formed in 2019 and is based in Newport Beach, California.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

15 May 2026
HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

15 May 2026
MicroAlgo Inc. announced a new algorithm for automating quantum circuit design, sending its shares up 13.18% to $4.55 at Thursday’s close and 20.88% higher in pre-market trading Friday. The company said its tool can generate and evaluate quantum circuits without pre-set specs and tested it on standard problems, but did not disclose customers, pricing, or a launch date.
IREN Stock Faces May 7 Test as AI Data Center Pivot, Microsoft Deal and $6 Billion Share-Sale Risk Collide
Previous Story

IREN Stock Faces May 7 Test as AI Data Center Pivot, Microsoft Deal and $6 Billion Share-Sale Risk Collide

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal
Next Story

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Go toTop